Insmed to showcase new data across three pillars at the american thoracic society 2022 international conference

--real-world evidence evaluating reduction in hospitalizations following initiation of use of arikayce® (amikacin liposome inhalation suspension) to be presented in poster discussion session-- --analysis of phase 2 willow study evaluating the benefit-risk profile of brensocatib in adult patients with non-cystic fibrosis bronchiectasis to be presented in mini-symposium-- bridgewater, n.j. , march 28, 2022 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that seven posters across three of its pillars—arikayce, brensocatib, and treprostinil palmitil inhalation powder (tpip)—will be presented at the american thoracic society (ats) 2022 international conference, taking place may 13-18, 2022, in san francisco.
INSM Ratings Summary
INSM Quant Ranking